. 2013 Mar 31;45(1):55–62. doi: 10.4143/crt.2013.45.1.55

Table 3.

Univariable survival analysis with proportional hazard regression in CRC patients who did not receive anti-EGFR therapies

graphic file with name crt-45-55-i003.jpg

CRC, colorectal cancer; EGFR, epidermal growth factor receptor; CI, confidence interval; PFS, progression free survival; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; XELOX, capecitabine plus oxaliplain; ECOG, Eastern Cooperative Oncology Group; PS, performance status; VEGF, vascular endothelial growth factor; FOLFIRI, 5-fluorouracil, leucovorin, and irinotecan.